Table 2 Values, notes, and sources for variables used to predict HCV infection reduction savings

Proportion of PWID HCV− (I)

25%

Average of values reported (10–40%)

Falade-Nwulia et al. [89]

Number of needles in circulation (N)

1,600,000

Increased by 33% due to additional syringe sources

Hunt and Parker [81]; German et al. [4]

Rate of needle sharing (s)

2.8%

Percent of injections with a shared needle

Park et al. [83]

Percentage of needles not bleached (d)

100%

Bluthenthal et al. [84]

Proportion of PWID HCV+ (q)

75%

Average of values reported (60–90%)

Falade-Nwulia et al. [89]

Probability of HCV infections from a single injection (t)

3%

Kwon et al. [86]; Kaplan and O’Keefe [85]

Number of sharing partners (m)

1.2

Per injection: ratio of receptive to distributive sharing

Park et al. [83]

SIF client reduction in needle-sharing (n)

70%

From Insite

Kerr et al. [40]

Number of SIF clients (N)

2100

Approximate monthly unique Insite injection room clients

Maynard [33]

Total PWID population (T)

20,950

Adjusted by authors from Baltimore MSA to City using race census data

Tempalski et al. [87]

Lifetime HCV treatment cost

$68,219

Adjusted for inflation

Razavi et al. [90]